Examples of 'on-treatment' in a sentence
Meaning of "on-treatment"
on-treatment (noun) - In the medical field, on-treatment refers to the period during which a patient is receiving a specific therapy or intervention for a condition
How to use "on-treatment" in a sentence
Basic
Advanced
on-treatment
One patient had on-treatment virologic failure.
The safety analyses were primarily based on the on-treatment period.
No subjects experienced on-treatment virologic failure or relapse.
No on-treatment viral breakthrough or post-treatment viral relapse has been observed.
No patient experienced on-treatment virologic failure or relapse.
On-treatment virologic failure was defined as meeting a virologic stopping rule or having viral breakthrough.
No subject experienced on-treatment virologic failure or relapse.
On-treatment virologic failure was defined as meeting a virologic stopping rule and / or having viral breakthrough.
No patient had on-treatment SAEs leading to death.
Treatment discontinuation in patients with inadequate on-treatment virologic response.
The one patient with on-treatment failure discontinued treatment early due to an adverse event.
Virologic failure relapse and on-treatment failure.
On-treatment analysis - analysis restricted to the time period that patients actually received treatment.
There was one relapse and no on-treatment virologic failures.
On-treatment virologic failure.
See also
There was one relapse and no on-treatment virologic failure.
On-treatment virologic failurea.
There was no relationship between on-treatment hsCRP levels and adverse events.
The total treatment duration was determined based on the patients ' individual on-treatment viral response.
Till now, few papers regarding on-treatment hepatic decompensation have been reported.
Patients who did not complete the study for any reason had higher on-treatment fracture rates.
On-treatment virologic failureb.
Hyperbilirubinemia is possibly the early warning feature of on-treatment hepatic decompensation.
The on-treatment biopsies were made 4 days after each adenovirus injection.
Two decompensated cirrhotic patients had on-treatment deaths which were not related to DAAs.
During the on-treatment period, 27 patients prematurely discontinued the study treatment.
Treatment discontinuation in patients with inadequate on-treatment virologic response OLYSIO in combination with sofosbuvir.
Table 11 summarises adjudicated bleeding events for the safety analysis set on-treatment period.
Outcome for patients without SVR On-treatment virologic failure Relapse b.
The analysis period for efficacy and safety is the main 6-month on-treatment period.
Pharmacokinetic data for the 1 patient with on-treatment virologic failure was consistent with non-adherence.
In the clinical study AGATE-I, one patient with HCV genotype 4a experienced virologic failure on-treatment failure.
On-treatment virologic failure Post-treatment relapse Other.
Outcome for patients without SVR On-treatment virologic failure.
The median time on-treatment in the Eklira Genuair and placebo groups was 1.1 and 1 year, respectively.
Prior partial responders Prior null responders Outcome for patients without SVR On-treatment failure Prior relapsers.
Among entecavir-treated patients on-treatment exacerbations had a median time of onset of 4-5 weeks.
Three GT3b TN subjects experienced relapse and two GT3b TEPRS subjects experienced on-treatment virologic failure.
Among tenofovir-treated patients on-treatment exacerbations typically occurred after 4-8 weeks of therapy.
Change from baseline to Last main 6-month on-treatment value.
The median time on-treatment in the Bretaris Genuair and placebo groups was 1.1 and 1 year, respectively.
No patients with genotype 1 HCV had on-treatment virologic failure.
Proportion ( % ) of patients with proven / probable Aspergillosis On-treatment period.
Virologic failure ( relapse and on-treatment failure ) Genotype 1a.
Proportion ( % ) of patients with proven / probable IFIs On-treatment period b.
Transformation to AP / BPf On-treatment transformation, n.
Controla Proportion ( % ) of patients with proven / probable Aspergillosis On-treatment periodb.
No new events of progression to AP / BC were reported on-treatment since the 2-year analysis.
Proportion ( % ) of patients with proven / probable Aspergillosis On-treatment periodb d e.
Otherd a No patients with genotype 1 HCV had on-treatment virologic failure.
